Italy’s Angelini Pharma has struck a deal to buy Catalyst Pharmaceuticals for $4.1 billion (€3.5 billion) to enter the US market.
Tag Archive for: Catalyst Pharmaceuticals
Santhera Pharmaceuticals Holding has exclusively granted the rights to commercialise its Duchenne muscular dystrophy drug vamorolone in North America to Catalyst Pharmaceuticals Inc.